PDX | Jotup

Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistan

Retrieved on:

星期三, 四月 10, 2024

WATERTOWN, Mass., April 10, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today announced data from two posters that the company presented at the American Association for Cancer Research (AACR) Annual Meeting.

Key Points:

“Uniquely enabled by AP3, we designed a selective and potent dual inhibitor of both WEE1 and PKMYT1, ACR-2316, designed for potent single agent activity.
We presented preclinical data showing its superior activity versus benchmark WEE1 and PKMYT1 single-agent inhibitors in multiple cancer models and look forward to advancing this compound into the clinic.
The complete responses observed with ACR-2316 in human tumor xenograft mouse models were associated with strong WEE1 and balanced PKMYT1 inhibition activity in tumors.
This corresponded with the subsequent upregulation of ACR-368 OncoSignature biomarkers, indicating that the OncoSignature assay can predict which ULDG sensitized tumors would be responsive to treatment with ACR-368.

Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate

Retrieved on:

星期三, 四月 10, 2024

In preclinical studies, data demonstrated that IPH45 effectively inhibits Nectin-4 expressing tumor growth both in vitro and in vivo, including in Enfortumab Vedotin (EV) refractory models.

Key Points:

In preclinical studies, data demonstrated that IPH45 effectively inhibits Nectin-4 expressing tumor growth both in vitro and in vivo, including in Enfortumab Vedotin (EV) refractory models.
Importantly, IPH45 shows stronger activity than EV, in multiple urothelial carcinoma PDX (patient-derived xenografted) mice models, across Nectin-4high and Nectin-4low expression levels.
“IPH45 is a novel and differentiated Nectin-4 ADC with preclinical efficacy in tumor types with various expression levels of Nectin-4.
Its exatecan payload allow for higher bystander-effect and a broader therapeutic index than MMAE-ADCs," commented Prof. Eric Vivier, DVM, PhD, Chief Scientific Officer at Innate Pharma.

Upgraded Points Highlights Airports With the Friendliest Staff in Latest Study

Retrieved on:

星期二, 四月 16, 2024

Pittsburgh International Airport, SNA, TSA, International airport, Point, PDX, PIT, JAX, IND, Airport, Jacksonville International Airport, Indianapolis International Airport, Federal Aviation Administration, Portland International Airport, Airline

PORTLAND, Ore., April 16, 2024 /PRNewswire/ -- The latest study from Upgraded Points is uncovering where passengers will catch a smile before they catch their flight.

Key Points:

PORTLAND, Ore., April 16, 2024 /PRNewswire/ -- The latest study from Upgraded Points is uncovering where passengers will catch a smile before they catch their flight.
"Our study acknowledges those airports where staff go the extra mile to ensure passenger satisfaction."
The Airports With the Friendliest Staff:
Portland International Airport (PDX) leads the pack with a friendliness score of 44/50.
Pittsburgh International Airport (PIT) is known for combining friendly staff with forward-thinking amenities, setting a higher standard for traveler satisfaction.

Frontier Medicines Presents New Data for First-In-Class Dual ON+OFF KRAS G12C Inhibitor FMC-376 at the AACR Annual Meeting

Retrieved on:

星期二, 四月 9, 2024

Lung cancer, Survival, NSCLC, Immunotherapy, Colorectal cancer, Central nervous system, Patient, CNS, Neoplasm, AACR, PDX, Clinical trial, Pancreatic cancer, Cancer, CRC, Metastasis, Proteome, PD-1, Pharmaceutical industry

- The Phase 1/2 PROSPER clinical trial is currently evaluating FMC-376 in patients with KRASG12C cancers, regardless of prior KRAS inhibitor therapy BOSTON and SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a clinical-stage precision medicine company seeking to unlock the proteome to advance transformational therapies against otherwise undruggable disease-causing targets, today presented new preclinical data on its KRASG12C inhibitor, FMC-376, at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, California. The new findings demonstrate FMC-376’s potential to overcome known mechanisms of innate and acquired resistance and in a CNS model of metastasis as a monotherapy and increase the efficacy of PD-1 immunotherapy in combination.

Key Points:

“These data demonstrate FMC-376’s unmatched potential to overcome over 90 percent of known resistance mechanisms, including those cancers that have become refractory to approved KRAS inhibitors.
The differentiated dual direct mechanism of action of FMC-376 offers the potential to overcome the resistance and lack of response seen with current KRASG12C single-acting treatments.
These results reinforce that FMC-376 has the potential to overcome limitations of single-acting KRASG12C inhibitors.
The combination of FMC-376 with an immune checkpoint inhibitor also leads to an increased response and survival in preclinical models.

NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024

Retrieved on:

星期一, 四月 8, 2024

Toxicity, Therapeutic index, KOSDAQ, Partnership, MMAE, Breast, Cancer, Spacecraft, CDX, AACR, PDX, Neoplasm, Pharmacokinetics, LCB, EC50, ADC

The poster presentation highlights LNBC74’s promising preclinical safety and anti-tumor activity.

Key Points:

The poster presentation highlights LNBC74’s promising preclinical safety and anti-tumor activity.
The presentation includes data demonstrating LNCB74’s high affinity and specificity for human B7-H4, a protein highly expressed on a range of solid tumors including breast, ovarian and endometrial cancers.
LNCB74 was shown to specifically bind to B7-H4 expressing tumor cells and was rapidly internalized in a target-dependent manner.
“These data underscore that LNCB74 is a promising candidate for the treatment of a variety of solid tumor indications.

Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update

Retrieved on:

星期五, 三月 29, 2024

PALO ALTO, Calif., March 29, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.

Key Points:

Vincerx presented preclinical data at the 2023 AACR Annual Meeting demonstrating significant activity in patient-derived xenograft (PDX) lymphoma mouse models.
Vincerx shared preclinical data at the 2023 ASH Annual Meeting showing superior activity and safety compared with commercially available B-cell targeted ADCs.
For the fourth quarter and full year 2023, Vincerx reported a net loss of $4.9 million, or $0.23 per share, and a net loss of $40.2 million, or $1.89 per share, respectively.
For the fourth quarter and full year 2022, Vincerx reported a net loss of $13.8 million, or $0.65 per share, and a net loss of $63.0 million, or $3.00 per share, respectively.

Alterome Therapeutics Presents Pre-Clinical Data Supporting the Development of Lead Program, an AKT1 E17K Inhibitor

Retrieved on:

星期一, 四月 8, 2024

Biotechnology, Pharmaceutical, Health, Oncology, AKT1, Mutation, Patient, Breast, Cancer, AACR, Hyperglycemia, PDX, Therapy, Pharmaceutical industry

Alterome Therapeutics, Inc. , a biopharmaceutical company pioneering the development of next generation, small molecule targeted therapies for the treatment of cancer, today reported promising preclinical data from their lead pipeline candidate, ALTA-2618, a mutation-selective inhibitor for AKT1 E17K driven cancers.

Key Points:

Alterome Therapeutics, Inc. , a biopharmaceutical company pioneering the development of next generation, small molecule targeted therapies for the treatment of cancer, today reported promising preclinical data from their lead pipeline candidate, ALTA-2618, a mutation-selective inhibitor for AKT1 E17K driven cancers.
ALTA-2618 is an orally bioavailable, mutant-selective, and covalent allosteric inhibitor of AKT1 E17K.
AKT1 E17K is a clinically validated oncogene that drives cancers, including breast, endometrial, and prostate cancers.
“We’re excited to present data at AACR featuring Alterome’s lead program, ALTA-2618, the first AKT1 E17K-selective inhibitor.

The START Center for Cancer Research Takes a Major Step Forward in its Mission to Bring the Hope of Cancer Research to Communities Globally

Retrieved on:

星期一, 四月 8, 2024

The START Center for Cancer Research, the world's largest global site network of early phase oncology clinical trials, sets its sights on expanding access to breakthrough research to all communities globally.

Key Points:

The START Center for Cancer Research, the world's largest global site network of early phase oncology clinical trials, sets its sights on expanding access to breakthrough research to all communities globally.
Slack, a respected leader in the clinical research industry, brings nearly 20 years of experience to grow START's mission of revolutionizing cancer clinical research.
With a global network spanning eight locations, including START San Antonio, START Midwest, START Mountain Region, START Madrid (FJD and CIOCC), START Barcelona, START Dublin, and START Lisbon, START is at the forefront of advancing cancer research.
Co-founders of The START Center for Cancer Research, Amita Patnaik, MD, FRCPC, and Kyriakos P. Papadopoulos, MD, will continue their pivotal roles as Co-directors of Clinical Research at START San Antonio.

Jacobio Pharma to Present Data of PARP7 Inhibitor and P53 Reactivator at the 2024 AACR Annual Meeting

Retrieved on:

星期二, 四月 9, 2024

Ovarian cancer, Immunotherapy, Carcinoma, Patient, SAN, Trial of the century, Abstract, CDX, AACR, PARP2, PDX, Pancreatic cancer, Safety, Stomach

P53 Y220C is the first tumor suppressor gene to enter into clinical study and has the potential to be used in combination with chemotherapy or oncogenic protein inhibitors.

Key Points:

P53 Y220C is the first tumor suppressor gene to enter into clinical study and has the potential to be used in combination with chemotherapy or oncogenic protein inhibitors.
As an important downstream target of the STING signaling pathway, PARP7 is expected to be used in combination with immunotherapy in the future.
Details for the 2024 AACR abstracts are as follows:
JAB-26766 is a potent, orally bioavailable PARP7 inhibitor with >1800-fold selectivity on PARP7 over PARP2.
The 2024 AACR Annual Meeting will be held in San Diego, California, U.S. from April 5th to April 10th.

Antengene Presents Four Preclinical Posters at AACR 2024

Retrieved on:

星期六, 四月 6, 2024

SHANGHAI and HONG KONG, April 5, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced the presentation of four preclinical posters at the 2024 American Association for Cancer Research Annual Meeting (AACR 2024), taking place from April 5th to April 10th at the San Diego Convention Center in San Diego, California, the United States.

Key Points:

SHANGHAI and HONG KONG, April 5, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced the presentation of four preclinical posters at the 2024 American Association for Cancer Research Annual Meeting (AACR 2024), taking place from April 5th to April 10th at the San Diego Convention Center in San Diego, California, the United States.
Study results showed that ATG-042 has the potential to elegantly target tumor cells while sparing healthy cells, with an attractive developability profile.
12:00 AM - 3:30 AM, April 10, 2024 (Beijing Time)
This preclinical study was designed to test the in vitro/in vivo efficacy, and preclinical pharmacokinetic (PK) properties of ATG-042.
This poster presents the discovery and validation of a novel, highly sensitive immunohistochemistry (IHC) antibody that selectively identifies CLDN18.2.